2018
DOI: 10.3389/fimmu.2018.00813
|View full text |Cite
|
Sign up to set email alerts
|

Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E

Abstract: The NT5E (CD73) molecule represents an ecto-5′-nucleotidase expressed on the cell surface of various cell types. Hydrolyzing extracellular adenosine monophosphate into adenosine and inorganic phosphate, NT5E performs numerous homeostatic functions in healthy organs and tissues. Importantly, NT5E can act as inhibitory immune checkpoint molecule, since free adenosine generated by NT5E inhibits cellular immune responses, thereby promoting immune escape of tumor cells. MicroRNAs (miRNAs) are small non-coding RNA m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
68
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
8
2

Relationship

2
8

Authors

Journals

citations
Cited by 82 publications
(69 citation statements)
references
References 95 publications
1
68
0
Order By: Relevance
“…The immunosuppressive nature of the membrane bound ectonucleotidase CD73 converting extracellular AMP to adenosine has been extensively reviewed 35,36 . Inhibition of CD73 was shown to suppress tumour growth in syngeneic mouse models [37][38][39] , and in fact, a first phase I/IB clinical trial investigating the preliminary activity of CD73 blocking antibody in combination with antibodies against anti PD-1 and/or adenosine A2A receptor in patients with advanced malignancies including PDA has been initiated in July 2018 40 .…”
Section: Discussionmentioning
confidence: 99%
“…The immunosuppressive nature of the membrane bound ectonucleotidase CD73 converting extracellular AMP to adenosine has been extensively reviewed 35,36 . Inhibition of CD73 was shown to suppress tumour growth in syngeneic mouse models [37][38][39] , and in fact, a first phase I/IB clinical trial investigating the preliminary activity of CD73 blocking antibody in combination with antibodies against anti PD-1 and/or adenosine A2A receptor in patients with advanced malignancies including PDA has been initiated in July 2018 40 .…”
Section: Discussionmentioning
confidence: 99%
“…Interestingly, shIF1 cells reveal significant increased expression of the CXC chemokine receptor 4 (CXCR4), which is involved in the inhibition of the activation and proliferation of NK cells by tumor cells [48,49] (Figure 7E). Moreover, shIF1 cells significantly increased the expression of the transcription factor SMAD3 and of the ecto-5'nucleotidase CD73/NT5E, which is under the control of SMAD3, an enzyme that generates adenosine in the tumor microenvironment leading to the suppression of multiple immune subsets including NK cells [50,51] ( Figure 7E). In addition, the mRNA of LDHA (two fold, false discovery rate (FDR) < 0.007) was also significantly increased in shIF1 cells, suggesting that they produce more lactate which might be released to the tumor microenvironment acting also as an immune metabolite that hampers immune surveillance and activation of NK cells [52] ( Figure 7E).…”
Section: Discussionmentioning
confidence: 99%
“…NT5E is also known as CD73 . CD73 is a membrane protein that cleaves extracellular nucleotides to nucleosides (Kordass, Osen, & Eichmuller, ). It is also considered as one of the surface markers for mesenchymal stem cells (Dominici et al, ).…”
Section: Discussionmentioning
confidence: 99%